veliparib

Phase 3Small molecule

veliparib is a small molecule that works as a PARP 1, 2 and 3 Inhibitor.[2] It is being investigated across 9 indications, with its most advanced program in Phase 3.[1]

veliparib is one of 273 small molecule programs targeting Breast Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

272

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CarcinomaActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

Breast CancerCompleted

Pancreatic CancerActive, not recruiting

GlioblastomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Metastatic Malignant Solid NeoplasmActive, not recruiting

Advanced Malignant Solid NeoplasmActive, not recruiting

Ann Arbor Stage III Non-Hodgkin LymphomaActive, not recruiting

Breast CarcinomaPhase 2

Active, not recruiting

Lung AdenocarcinomaPreclinical

Active, not recruiting

Breast CancerPhase 3

Completed

Pancreatic CancerPhase 2

Active, not recruiting

GlioblastomaPreclinical

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Metastatic Malignant Solid NeoplasmPreclinical

Active, not recruiting

Advanced Malignant Solid NeoplasmPhase 1

Active, not recruiting

Ann Arbor Stage III Non-Hodgkin LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

veliparib

AbbVie

Phase 3

11 2

Lexiscan

Astellas

Preclinical

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 7

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 8

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 9

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1 10

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Breast Cancer

NCT01251874

Phase 2Active, not recruiting

Acute Myeloid Leukemia

NCT03289910

PreclinicalActive, not recruiting

Glioblastoma

NCT02152982

PreclinicalActive, not recruiting

Lung Adenocarcinoma

NCT01386385

Q1 2027

Phase 1Active, not recruiting

Breast Carcinoma

NCT01366144

Phase 2Active, not recruiting

Locally Advanced Pancreatic Adenocarcinoma

NCT01585805

Clinical

Trials by Indication[1]

Breast Cancer11 trials

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 3·NCT02163694·513 enrolled

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

No longer available·UUniversity of Washington··NCT02985658

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01818063·9 enrolled

Show 8 more trials

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01251874·44 enrolled

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT01506609·294 enrolled

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01149083·77 enrolled

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT01477489·33 enrolled

Pre-Operative Radiation and Veliparib for Breast Cancer

Completed·RRichard Zellars·Phase 1·NCT01618357·19 enrolled

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 3·NCT02032277·634 enrolled

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Completed·UUniversity of Washington·Phase 1·NCT01104259·50 enrolled

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02595905·344 enrolled

Non-Small Cell Lung Cancer7 trials

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Terminated· AbbVie logo

AbbVie·Phase 1/2·NCT02412371·48 enrolled

Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT01657799·307 enrolled

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Completed· AbbVie logo

AbbVie·Phase 3·NCT02264990·595 enrolled

Show 4 more trials

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Completed· AbbVie logo

AbbVie·Phase 3·NCT02106546·970 enrolled

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· AbbVie logo

AbbVie·Phase 1·NCT02944396·25 enrolled

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01282333·44 enrolled

A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT01560104·160 enrolled

Solid Tumors5 trials

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Completed·AAbbott·Phase 2·NCT01193140·24 enrolled

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01017640·20 enrolled

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01199224·27 enrolled

Show 2 more trials

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01853306·71 enrolled

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01617928·12 enrolled

Ovarian Cancer4 trials

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Completed· AbbVie logo

AbbVie·Phase 1·NCT02483104·9 enrolled

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Completed·VVejle Hospital·Phase 1/2·NCT01690598·22 enrolled

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Completed·VVejle Hospital·Phase 1/2·NCT01472783·49 enrolled

Show 1 more trial

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Withdrawn· AbbVie logo

AbbVie·Phase 1·NCT03400306

Fallopian Tube Cancer3 trials

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01459380·41 enrolled

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01145430·45 enrolled

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01749397·29 enrolled

47 more indications

Cervical Cancer2 trials

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01266447·27 enrolled

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01281852·37 enrolled

Refractory Solid Tumors2 trials

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02723864·53 enrolled

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00387608·23 enrolled

Patients With Advanced Solid Tumors2 trials

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01154426·31 enrolled

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01233505·16 enrolled

Pancreatic Cancer2 trials

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

Completed·—·Phase 1·NCT01908478·34 enrolled

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02890355·123 enrolled

Patients With Solid Tumors2 trials

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02631733·18 enrolled

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT02009631·45 enrolled

Primary Peritoneal Cancer2 trials

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00989651·431 enrolled

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated· AbbVie logo

AbbVie·Phase 3·NCT02470585·1,140 enrolled

Advanced Solid Tumors2 trials

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01063816·79 enrolled

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT02210663·16 enrolled

Metastatic1 trial

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00576654·73 enrolled

Advanced Solid Cancer1 trial

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00535119·107 enrolled

Acute Leukemia1 trial

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01139970·66 enrolled

Small Cell Lung Cancer1 trial

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT02289690·221 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01281150·22 enrolled

SCLC1 trial

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Unknown status·CCentral European Society for Anticancer Drug Research·Phase 1·NCT03227016·30 enrolled

Myeloproliferative Disorder1 trial

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00588991·12 enrolled

Locally-advanced Rectal Cancer1 trial

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02921256·363 enrolled

Prostate Cancer1 trial

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01576172·159 enrolled

Advanced Solid Malignancies1 trial

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01264432·34 enrolled

ESS1 trial

Expanded Access to Veliparib

No longer available· AbbVie logo

AbbVie··NCT03123211

Lymphoma1 trial

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Completed·NNorthwestern University·Phase 1·NCT03061188·15 enrolled

Multiple Myeloma1 trial

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01326702·43 enrolled

Glioma1 trial

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01514201·66 enrolled

PARP Inhibitor1 trial

Response to PARP Inhibitor Predicted by the RAD51 Assay

Withdrawn·UUniversity Medical Center Groningen·Phase 2·NCT03044795

Testicular Germ Cell Cancer1 trial

Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Completed·NNational Cancer Institute, Slovakia·Phase 2·NCT02860819·15 enrolled

Metastatic Colorectal Cancer1 trial

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT02305758·130 enrolled

Malignant Solid Tumors1 trial

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00892736·98 enrolled

Chemotherapy1 trial

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT02033551·47 enrolled

Solid Tumor1 trial

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Completed· AbbVie logo

AbbVie·Phase 1·NCT01123876·60 enrolled

Recurrent or Refractory1 trial

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00946335·31 enrolled

Tumor1 trial

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01827384·208 enrolled

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01711541·24 enrolled

Recurrent Epithelial Ovarian1 trial

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01540565·52 enrolled

Neuroendocrine Tumor1 trial

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02831179

Patients With Locally Advanced Rectal Cancer1 trial

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Completed· AbbVie logo

AbbVie·Phase 1·NCT01589419·32 enrolled

Glioblastoma1 trial

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02152982·447 enrolled

Lung Adenocarcinoma1 trial

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT01386385·53 enrolled

Anaplastic Astrocytoma1 trial

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03581292·38 enrolled

Recurrent Lung Small Cell Carcinoma1 trial

A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01638546·97 enrolled

Metastatic Malignant Solid Neoplasm1 trial

A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT01012817·88 enrolled

Locally Advanced Pancreatic Adenocarcinoma1 trial

A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01585805·83 enrolled

Locally Advanced Unresectable Breast Carcinoma1 trial

Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01351909·35 enrolled

Breast Carcinoma1 trial

An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01366144·94 enrolled

Ann Arbor Stage III Non-Hodgkin Lymphoma1 trial

A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT00740805·81 enrolled

Advanced Malignant Solid Neoplasm1 trial

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01434316·121 enrolled

Extensive-stage Small-cell Lung Cancer1 trial

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Preclinical·NCT01642251·156 enrolled

Acute Myeloid Leukemia1 trial

NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03289910·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 84 trial records for veliparib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — veliparib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for veliparib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PARP 1, 2 and 3 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

veliparib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Breast Cancer11 trials

Non-Small Cell Lung Cancer7 trials

Solid Tumors5 trials

Ovarian Cancer4 trials

Fallopian Tube Cancer3 trials

Cervical Cancer2 trials

Refractory Solid Tumors2 trials

Patients With Advanced Solid Tumors2 trials

Pancreatic Cancer2 trials

Patients With Solid Tumors2 trials

Primary Peritoneal Cancer2 trials

Advanced Solid Tumors2 trials

Metastatic1 trial

Advanced Solid Cancer1 trial

Acute Leukemia1 trial

Small Cell Lung Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

SCLC1 trial

Myeloproliferative Disorder1 trial

Locally-advanced Rectal Cancer1 trial

Prostate Cancer1 trial

Advanced Solid Malignancies1 trial

ESS1 trial

Lymphoma1 trial

Multiple Myeloma1 trial

Glioma1 trial

PARP Inhibitor1 trial

Testicular Germ Cell Cancer1 trial

Metastatic Colorectal Cancer1 trial

Malignant Solid Tumors1 trial

Chemotherapy1 trial

Solid Tumor1 trial

Recurrent or Refractory1 trial

Tumor1 trial

Glioblastoma Multiforme1 trial

Carboplatin1 trial

Head and Neck Cancer1 trial

Recurrent Epithelial Ovarian1 trial

Neuroendocrine Tumor1 trial

Patients With Locally Advanced Rectal Cancer1 trial

Glioblastoma1 trial

Lung Adenocarcinoma1 trial

Anaplastic Astrocytoma1 trial

Recurrent Lung Small Cell Carcinoma1 trial

Metastatic Malignant Solid Neoplasm1 trial

Locally Advanced Pancreatic Adenocarcinoma1 trial

Locally Advanced Unresectable Breast Carcinoma1 trial

Breast Carcinoma1 trial

Ann Arbor Stage III Non-Hodgkin Lymphoma1 trial

Advanced Malignant Solid Neoplasm1 trial

Extensive-stage Small-cell Lung Cancer1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News